FibroGen’s headquarters in San Francisco, US. Credit: Sundry Photography via Getty Images. AstraZeneca has agreed to acquire FibroGen’s China subsidiary for approximately $160m, securing full
Bluebird bio has found a new nest with Carlyle and SK Capital. Credit: pchoui via Getty Images. Bluebird bio will be acquired by investment firms
NICE estimates that these therapies could help nearly 700 patients per year in England. Credit: krisanapong detraphiphat via Getty Images. Two blood cancer treatments will
Zealand Pharma is based in Denmark. Credit: Zealand Pharma via LinkedIn. Zealand Pharma’s search for a partner for its amylin-based obesity therapy petrelintide remains ongoing,
The Phase IIb study enrolled 250 adult patients with treatment-resistant depression. Credit: Justin Paget via Getty Images. Supernus Pharmaceutical’s stock declined following the release of
AWS reported $107.6bn in revenue in 2024. Credit: Noah Berger via Getty Images. Amazon Web Services (AWS) and US-based Memorial Sloan Kettering Cancer Center (MSK)
There is a demand for new, non-addictive treatments for opioid use disorder. Credit: sorbetto via Getty Images. Glucagon-like peptide receptor agonists (GLP-1RAs) like Novo Nordisk’s
If approved, lenacapavir would be the first twice-yearly HIV prevention choice. Credit: Ulrich Baumgarten via Getty Images. Gilead is edging closer to an approval for
Regeneron and Sanofi have collaborated on Dupixent since 2007. Credit: The Washington Post via Getty Images. Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised
TGCT is a rare, non-cancerous tumour affecting the joints, tendons, or joint tissue. Credit: Kinga Krzeminska via Getty Images. Ono Pharmaceutical has secured approval from